Discover
ELTX
Elicio Therapeutics, Inc.
3.36
1 x 2.70
1 x 4.28
bid
ask
-
1.78
34.63%
01:19 PM
timesize
| Ytd | -57.79% | |
| 1y | -57.20% |
3.31
day range
3.80
2.66
52 week range
16.00
| Open | 3.60 | Prev Close | 5.14 | Low | 3.31 | High | 3.80 | Mkt Cap | 64.13M |
| Vol | 3.33M | Avg Vol | 1.45M | EPS | -2.36 | P/E | N/A | Forward P/E | -1.96 |
| Beta | N/A | Short Ratio | 2.49 | Inst. Own | 5.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.65 | 200-d Avg | 9.65 | 1yr Est | 9.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.81 | -1.39 | -0.58 | -71.60% |
| 2024-08-13 | 2024-06 | -0.96 | -0.64 | 0.32 | 33.33% |
| 2024-08-13 | 2024-06 | -0.96 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -1.09 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -1.09 | -1.15 | -0.06 | -5.50% |
| 2024-03-29 | 2023-12 | -0.79 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-31 | Jones Trading | Upgrade | Buy | |
| 2024-08-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-01 | Oppenheimer | Upgrade | Perform | Perform |
Profile
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-21 | CHUDNOVSKY YEKATERINA | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-12-15 | DEMUTH PETER | Officer | 381.00 | Conversion of Exercise of derivative security |
| 2024-11-25 | VENKATESAN JAY R | Director | 180.53K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 245.26K | 1.23M | 2.27% |
| 2024-09-29 | Geode Capital Management, LLC | 71.57K | 360.02K | 0.66% |
| 2024-09-29 | CM Management, LLC | 50.00K | 251.50K | 0.46% |
| 2024-09-29 | Northern Trust Corporation | 30.77K | 154.77K | 0.29% |
| 2024-09-29 | State Street Corporation | 21.90K | 110.16K | 0.20% |
| 2024-09-29 | Blackrock Inc. | 19.69K | 99.06K | 0.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 203.48K | 1.02M | 1.89% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 41.47K | 208.61K | 0.38% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 34.42K | 173.14K | 0.32% |
| 2024-10-30 | iShares Micro Cap ETF | 17.08K | 85.90K | 0.16% |
| 2024-09-29 | Northern Small Cap Core Fund | 13.00K | 65.39K | 0.12% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 12.50K | 62.88K | 0.12% |